A simulation platform to examine heterogeneity influence on treatment.
Although a protocol aims to guide treatment management and optimize overall outcomes, the benefits and harms for each individual vary due to heterogeneity. Some protocols integrate clinical and genetic variation to provide treatment recommendation; it is not clear whether such integration is sufficient. If not, treatment outcomes may be sub-optimal for certain patient sub-populations. Unfortunately, running a clinical trial to examine such outcome responses is cost prohibitive and requires a significant amount of time to conduct the study. We propose a simulation approach to discover this knowledge from electronic medical records; a rapid method to reach this goal. We use the well-known drug warfarin as an example to examine whether patient characteristics, including race and the genes CYP2C9 and VKORC1, have been fully integrated into dosing protocols. The two genes mentioned above have been shown to be important in patient response to warfarin.
Center for Biomedical Informatics, Harvard Medical School, Boston, MA.
Chih-Lin
CL
Chi
Vincent A
VA
Fusaro
Prasad
P
Patil
Matthew A
MA
Crawford
Charles F
CF
Content
Peter J
PJ
Tonellato